文献速递乳腺癌

在UK Biobank中评估BCSC与MammoRisk联合多基因风险评分313对乳腺癌风险预测的价值

Evaluating breast cancer screening consortium and MammoRisk plus polygenic risk score 313 for breast cancer risk prediction in UK Biobank.
PubMed 文献 · Eur J Cancer · 2025-11-06

本研究基于UK Biobank女性队列,评估BCSC与MammoRisk模型单独或联合313变异多基因风险评分(PRS313)的校准与区分度,主要终点为欧洲血统个体5年内浸润性乳腺癌诊断。结果显示加入PRS313可提升两种模型的区分度,欧洲血统者tdAUROC分别提高+0.083和+0.084至0.639和0.641,非欧洲血统者提升较小;校准改善仅见于欧洲血统者。结论支持PRS联合临床模型提升预测,但跨血统泛化性有限。

要点

  • 加入PRS313可提升BCSC与MammoRisk对乳腺癌的区分度。
  • 欧洲血统者tdAUROC提高约+0.08,非欧洲血统者仅约+0.03。
  • 校准改善仅见于欧洲血统者,跨血统泛化性受限。

核心结论

  • 研究支持将PRS313整合入临床风险模型以提升乳腺癌风险预测。
  • PRS313对不同血统人群临床模型性能的提升存在差异,提示当前基于PRS的筛查模型泛化性有限。

研究设计与样本

  • 基于UK Biobank女性参与者队列,评估BCSC与MammoRisk模型联合或不联合PRS313的校准与区分度。
  • 因无乳腺密度数据,将四种预测风险按其在人群中的频率加权平均。
  • 主要终点为欧洲血统个体5年内浸润性乳腺癌诊断,并探索非欧洲血统个体的模型性能。

主要发现

  • 加入PRS313后,BCSC与MammoRisk在欧洲血统者中tdAUROC分别提高+0.083和+0.084,达到0.639和0.641。
  • 非欧洲血统者中tdAUROC分别提高+0.033和+0.032,达到0.610和0.609。
  • 校准改善仅见于欧洲血统者,ICI分别降低0.00005和0.00027,达到0.00088和0.00078。

临床怎么用

  • 在临床风险模型中整合PRS313可能改善乳腺癌风险预测,但需注意血统差异对模型性能的影响。

局限性

  • 研究缺乏乳腺密度数据,采用频率加权平均处理四种预测风险。
  • 非欧洲血统人群中PRS313带来的性能提升较小且校准未改善,限制其通用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Polygenic risk scores combined to clinical parameters provide promising avenues for breast cancer risk prediction. We evaluated the performance of the Breast Cancer Screening Consortium (BCSC) and the MammoRisk (MR) with and without 313-variant polygenic risk score (PRS313) in the UK Biobank cohort. METHODS: We used data from female participants enrolled in the UK Biobank cohort to assess model calibration and discrimination of BCSC and MR with and without PRS313. Mammographic density data were not available, therefore, the four predicted risks were averaged with a weight corresponding to their frequencies in the population. The primary endpoint was the diagnosis of invasive breast cancer within 5 years among individuals of European ancestry. We also explored the performance parameters of the risk models among individuals of non-European ancestry. RESULTS: Adding PRS313 improved the discriminative performance for both BCSC and MR scores across ancestry groups. Among participants of European ancestry, time-dependent area under the receiver operating characteristic curve (tdAUROC) increased by + 0.083 and + 0.084, respectively, reaching 0.639 and 0.641. Among participants of non-European ancestry, smaller improvement were observed (tdAUROC = +0.033 and +0.032, respectively) to tdAUROC of 0.610 and 0.609. Calibration improvement was limited to participants from European ancestry, with integrated calibration index (ICI) decreasing by 0.00005 and 0.00027, to reach 0.00088 and 0.00078, respectively. CONCLUSIONS: Our findings support the potential of integrating PRS with clinical risk models to enhance breast cancer risk prediction. The differential contribution of adding PRS313 to the performance of clinical models across ancestries underscores the limitations in the generalizability of current PRS-based screening models for breast cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rassy E, Delaloge S, Karimi M, et al. Evaluating breast cancer screening consortium and MammoRisk plus polygenic risk score 313 for breast cancer risk prediction in UK Biobank. Eur J Cancer. 2025. PMID: 41223562. doi:10.1016/j.ejca.2025.116096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。